Clinical Pharmacogenetics Implementation Consortium (CPIC)

About:

CPIC is an international consortium of individual volunteers and a small dedicated staff.

Website: https://cpicpgx.org/

Twitter/X: cpicpgx

Top Investors: National Institutes of Health

Description:

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care. One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs. CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications). CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.

Total Funding Amount:

$5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Memphis, Tennessee, United States

Founded Date:

2009-01-01

Contact Email:

contact(AT)cpicpgx.org

Founders:

Number of Employees:

11-50

Last Funding Date:

2019-02-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai